11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess
Year: 2014
Type: article
Abstract: The adverse metabolic effects of prescribed and endogenous glucocorticoid (GC) excess, Cushing syndrome, create a significant health burden. We found that tissue regeneration of GCs by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), rather than circulating delivery, is critical to developing the phenotype of GC excess; 11β-HSD1 KO mice with circulating GC excess are protected from the glucose intolerance, hyperinsulinemia, hepatic steatosis, adiposity, hypertension, myopathy, and dermal atrophy of Cushing syndrome. Whereas liver-specific 11β-HSD1 KO mice developed a full Cushingoid phenotype, adipose-specific 11β-HSD1 KO mice were protected from hepatic steatosis and circulating fatty acid excess. These data challenge our current view of GC action, demonstrating 11β-HSD1, particularly in adipose tissue, is key to the development of the adverse metabolic profile associated with circulating GC excess, offering 11β-HSD1 inhibition as a previously unidentified approach to treat Cushing syndrome.
Institutions: University of Birmingham, University of Leeds
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Hexose-6-phosphate dehydrogenase and Glucose-6-phosphate: novel regulators of corticosteroid hormone metabolism and adrenal function., Investigating hexose-6-phosphate dehydrogenase in the control of skeletal muscle function and carbohydrate metabolism, G3928680135, Centre for Musculoskeletal Ageing Research, NIHR Senior Investigator Award
OpenAlex ID: W2059237923
